Get startedLog in
    Picture of Palatin Technologies logo

    PTN — Palatin Technologies News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    All News

    Brief: FDA Confirms Acceptability Of Palatin's Remaining Phase 3 Pivotal Clinical Trials

    Picture of Palatin Technologies logoPalatin Technologies
    28/08/2024 12:39
    Aug 28 (Reuters) - Palatin Technologies Inc  PTN.A :
    * FDA CONFIRMS ACCEPTABILITY OF PALATIN'S REMAINING PHASE 3
PIVOTAL CLINICAL TRIALS FOR PL9643 IN DRY EYE DISEASE (DED)
    * PALATIN TECHNOLOGIES INC - CURRENTLY ANTICIPATE PATIENT
ENROLLMENT TO START IN 4Q CALENDAR YEAR 2024
    * PALATIN TECHNOLOGIES: TOPLINE RESULTS CURRENTLY EXPECTED
IN 4Q
CALENDAR YEAR 2025

Source text for Eikon:  ID:nPn4jwY3a 
Further company coverage:  PTN.A 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Palatin Technologies

    See all news